[Antagonists of ionotropic glutamate receptors as the object of research in psychopharmacology].
Ionotropic glutamate receptors antagonists are now widely considered as potential medications for a variety of disorders, such as seizures, neurodegenerative diseases, stroke, and opiate tolerance and dependence. There is a growing body of evidence suggesting that the safest drugs are to be found amongst antagonists acting at glycine and polyamine sites of NMDA-receptor complex, low-affinity channel blockers, subtype-selective competitive NMDA-receptor antagonists, as well as non-NMDA glutamate receptors antagonists. These antagonists exhibit little or no abuse liability and are less likely to induce phencyclidine-like attention deficits and disruption of sensomotor gating. Meanwhile, these drugs retain most of the potentially useful properties, including anxiolytic and antidepressant effects.
Bespalov
A Iu
AIu
Department of Psychopharmacology, A. V. Valdman Institute of Pharmacology, St. Petersburg State I. P. Pavlov Medical University.
Evartau
E E
EE
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D000928:Antidepressive Agents / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006213:Hallucinogens / Q000494:pharmacology; D007859:Learning Disabilities / Q000188:drug therapy / Q000503:physiopathology; D008569:Memory Disorders / Q000188:drug therapy / Q000503:physiopathology; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000502:physiology; D012106:Research
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D018691:Excitatory Amino Acid Antagonists; D006213:Hallucinogens; D011619:Psychotropic Drugs; D016194:Receptors, N-Methyl-D-Aspartate